PR Newswire - Transcenta Debuts Encouraging Phase II Data from F...
Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression, including in patients with PD-L1 CPS<5. PRINCETON, N.J. and SUZHOU, China, May 24, 2024 /PRNew...
Read More


ภาษาไทย
English